<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02769091</url>
  </required_header>
  <id_info>
    <org_study_id>TV45478-IMM-20019</org_study_id>
    <nct_id>NCT02769091</nct_id>
  </id_info>
  <brief_title>A Study in Adult Patients With Nonalcoholic Steatohepatitis Who Also Have Type 2 Diabetes</brief_title>
  <acronym>NASH</acronym>
  <official_title>A 24-Week, Randomized, Double-blind, Placebo-controlled, Efficacy and Safety Study of 80 mg TEV-45478 Once Daily as Treatment in Adult Patients With Nonalcoholic Steatohepatitis (NASH) Who Also Have Type 2 Diabetes Mellitus - GN</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Teva Branded Pharmaceutical Products, R&amp;D Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Teva Pharmaceutical Industries</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the effect of TEV-45478, as compared with placebo, on
      liver health and liver fat content in patients with T2DM who also have Nonalcoholic
      Steatohepatitis (NASH).
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Business decision
  </why_stopped>
  <start_date type="Actual">September 30, 2016</start_date>
  <completion_date type="Anticipated">February 28, 2018</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>serum Alanine Transaminase (ALT) levels response, defined as ALT value within reference range of &lt;35 IU/L for women and &lt;40 IU/L for men</measure>
    <time_frame>Week 24</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>liver fat response, defined as a reduction of ≥6% at week 24 compared to screening by the MRI-Proton Density Fat Fraction (PDFF)</measure>
    <time_frame>Week 24</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants with Adverse Events</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>percent change from baseline in ALT</measure>
    <time_frame>Baseline, Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>percent change from baseline in ALT</measure>
    <time_frame>Baseline, Weeks 2, 4, 8, 12, 16, 20, and 24 (or early withdrawal)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>percent change from baseline in Aspartate Aminotransferase (AST)</measure>
    <time_frame>Baseline, Weeks 2, 4, 8, 12, 16, 20, and 24 (or early withdrawal)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change from baseline in AST</measure>
    <time_frame>Baseline, Weeks 2, 4, 8, 12, 16, 20, and 24 (or early withdrawal)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change from baseline in ALT</measure>
    <time_frame>Baseline, Weeks 2, 4, 8, 12, 16, 20, and 24 (or early withdrawal)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in glycosylated hemoglobin ((HbA1c)</measure>
    <time_frame>Baseline, Weeks 4, 12, and 24 (or early withdrawal)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in liver fibrosis measured using transient elastography (with Fibroscan)</measure>
    <time_frame>Baseline, Week 24 (or early withdrawal)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Nonalcoholic Steatohepatitis</condition>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>TEV-45478</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>80 mg (2x40mg) tablets once daily for up to 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TEV-45478</intervention_name>
    <description>80 mg (2x40mg) tablets once daily for up to 24 weeks</description>
    <arm_group_label>TEV-45478</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The patient is female or male and aged 18 to 65 years, inclusive with a history of
             Type 2 Diabetes Mellitus (T2DM) and on stable medication for diabetes or insulin or a
             combination thereof for at least 3 months prior to screening.

          -  The patient has a NASH Activity Score (NAS) of ≥4, with or without evidence of
             fibrosis, with a score of at least 1 in steatosis and lobular inflammation the
             subcomponents of NAS and a hepatocyte ballooning score of at least 1 score based on
             historical histological evaluation of liver biopsy within 12 months prior to
             randomization.

          -  The patient has a historical diagnosis of NASH, established no more than 12 months
             prior to randomization based on histology (liver biopsy).

          -  The patient has an ALT level at screening between 45 and 105 IU/L, inclusive, for
             women and between 55 and 120 IU/L, inclusive for men, at one other occasion during the
             24-weeks prior to screening.

          -  The patient has an MRI determined liver fat fraction of equal to or higher than 6% at
             Screening

               -  Additional criteria apply, please contact the investigator for more information

        Exclusion Criteria:

          -  The patient has a history of chronic liver disease other than NASH eg, chronic or
             acute hepatitis, autoimmune, viral (A, B, C), genetic hepatitis, drug induced
             hepatotoxicity, Wilson's disease, alcoholic liver diseases, or any other non-NASH
             active liver disease.

          -  The patient has active cancer or a history of a malignant disease (except basal cell
             carcinoma of the skin) within 5 years prior to screening or any history of bladder
             cancer.

          -  The patient had an unstable metabolic condition (ie, with a history of weight loss or
             weight gain of &gt;5 kg within 24 weeks prior to screening)

          -  The patient has a history of bariatric surgery within 5 years prior to screening.

          -  The patient has received mercaptopurine or azathioprine previously within 1 year prior
             to screening

          -  The patient has taken within 7 days prior to the first dose of study drug (or is
             anticipated to take during the study) anticholinergic or other drugs known to affect
             gastrointestinal (GI) motility, proton-pump inhibitors, or other drugs known to affect
             gastric acidity or use of allopurinol.

          -  The patient has received oral antibiotics within the last 4 weeks prior to
             randomization (day 1).

          -  The patient has received treatment within the last 30 days with any drugs known to
             induce or inhibit endogenous hepatic drug metabolism (eg, barbiturates,
             phenothiazines, cimetidine, carbamazepine) or anti-coagulant therapy (eg, heparin,
             warfarin, acenocoumarol).

          -  The patient has Type 1 Diabetes Mellitus (T1DM) or poorly controlled T2DM

          -  The patient has a body mass index (BMI) &lt;25 kg/m2.

          -  The patient has a history of diabetic gastroparesis or has had gastric bypass surgery
             within the last 5 years.

          -  The patient has a history of pancreatitis.

          -  The patient has a history of persistent intestinal obstruction, bowel perforation,
             uncontrolled GI bleed or abdominal abscess or infection or toxic megacolon or
             inflammatory bowel disease (IBD)

          -  The patient has a history of coronary angioplasty, coronary stent placement, coronary
             bypass surgery, unstable angina, myocardial infarction, transient ischemic events, or
             stroke within 24-weeks prior to screening.

          -  The patient is classified as Class II-IV via New York Heart Association

          -  The patient has a history of drug abuse (defined as illicit drug use) or a history of
             excessive alcohol abuse (defined as regular or daily consumption of more than 2
             alcoholic drinks per day for women or 3 alcoholic drinks per day for men) within 1
             year prior to the screening visit.

               -  Additional criteria apply, please contact the investigator for more information
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Teva Medical Expert, MD</last_name>
    <role>Study Director</role>
    <affiliation>TEVA</affiliation>
  </overall_official>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 9, 2016</study_first_submitted>
  <study_first_submitted_qc>May 9, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 11, 2016</study_first_posted>
  <last_update_submitted>January 2, 2018</last_update_submitted>
  <last_update_submitted_qc>January 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

